US 10,478,497 B2Granted

Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer

AssigneeHybrigenics

InventorsSusan Benjamin, Cécile Planquette, Rémi Delansorne

Life of this patent

Estimating the term…

Abstract

The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.

Claims1

Dependent claims

The combination of inecalcitol with an anti-CD38 agent, wherein said anti-CD38 agent is selected from the group consisting of daratumumab, isatuximab, and MOR202.

Dependencies are inferred from the claim text.

Facts

Application: 15/655,394Filed 20 Jul 2017 · us provisional application
Priority: 20 Jul 2016
Published: US 2018/0021432 A125 Jan 2018
Granted: 19 Nov 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61K 31/047
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates: having two or more hydroxy groups, e.g. sorbitol
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Family

Application62/364,561Us provisional application · filed 20 Jul 2016
US 2018/0021432 A1Pre-grant publication · published 25 Jan 2018
US 10,478,497 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results